Case Reports in Infectious Diseases

Case Reports in Infectious Diseases / 2020 / Article

Case Report | Open Access

Volume 2020 |Article ID 9603428 |

Irma Huayanay, Leonardo Pozo, Salman Bangash, Denisse Ramirez, Luis Rosas, Renzo Arauco Brown, "An Unusual Case of Campylobacter jejuni Gastroenteritis Presenting with Acute Reversible Encephalopathy in an Immunocompetent Host", Case Reports in Infectious Diseases, vol. 2020, Article ID 9603428, 6 pages, 2020.

An Unusual Case of Campylobacter jejuni Gastroenteritis Presenting with Acute Reversible Encephalopathy in an Immunocompetent Host

Academic Editor: Gernot Walder
Received02 Jan 2020
Revised21 Mar 2020
Accepted19 Jun 2020
Published06 Jul 2020


Campylobacter jejuni gastroenteritis is the most frequent organism associated with acute infectious diarrhea worldwide. The clinical presentation involves fever, diarrhea, rigors, and myalgias. Other extraintestinal symptoms that have been described involve delirium and other neurological complications, and the most well-known is Guillain-Barré, where there is cross-reactivity between the gastrointestinal tract and the brain. Despite previously described multiple neurological complications, there is a lack of clinical data on the association of Campylobacter-related gastroenteritis with acute encephalopathy in immunocompetent patients. The type of population, immunocompetent stage, and unfamiliarity with the clinical presentation makes this a challenging diagnosis for clinicians. We report a case of Campylobacter gastroenteritis associated with acute encephalopathy in an immunocompetent patient.

1. Introduction

Campylobacter jejuni (C. jejuni) is the most frequent organism associated with acute bacterial gastroenteritis around the world [1]. The high incidence of Campylobacter diarrhea, as well as its duration and possible complications, makes it highly important from a socioeconomic perspective [2]. It is estimated to cause 1.3 million human illnesses every year with 96 million cases in 2010 in the United States [3]. The clinical presentation is characterized mainly by abdominal pain and diarrhea. A prodrome phase characterized by fever, rigors, myalgias, and occasional delirium has been described [2]. The most well-known postinfectious neurological complications are Guillain-Barré syndrome (GBS) and Miller-Fisher syndrome (MFS) [4]. Furthermore, worldwide the incidence is 1 to 2 in 100,000 and 1 to 2 in 1,000,000, for GBS and MFS, respectively [5]. Nearly 30–40% of GBS patients had C. jejuni infection 2 weeks prior to onset of neurological symptoms [6]. Other less frequent neurological complications include Bickerstaff’s brainstem encephalitis, acute transverse myelitis, and acute disseminated encephalomyelitis (ADEM) [4, 79]. We present a case of Campylobacter gastroenteritis presenting with associated encephalopathy in an immunocompetent patient.

2. Case

A twenty-five-year-old female with unremarkable past medical history was brought to the emergency department due to progressive altered mental status. Per family report, the patient was in her usual state of health until one week before this admission when she started to experience abdominal pain and diarrhea. The patient’s mother described episodes of anxiety and unusual behavior-associated confusion specially the day before admission.

On the day of admission, the patient sought medical attention at an outpatient clinic. While in the office, she became confused and later she experienced a witnessed seizure. The patient received a dose of lorazepam prior to arrival at the hospital. On arrival to the emergency department, she was found unresponsive with a Glasgow Coma Scale of six. She was afebrile and tachycardic with a heart rate of 115 beats per minute. The rest of her vital signs were within normal limits.

Her physical exam was remarkable for generalized decreased muscle tone and no clear focal deficits. The patient was intubated for airway protection. She was given a loading dose of levetiracetam and was admitted to the neurosciences intensive care unit.

Her initial laboratory tests showed respiratory alkalosis with an elevated white blood cell count at 11.6 th/μl with 76.5% of neutrophils. Her complete metabolic panel showed hypokalemia. Her urine toxicology, serum alcohol levels, and urine analysis were unremarkable. C-reactive protein was 3.3 mg/dL, and her lactic acid was 1.2 mmol/L. Blood tests are summarized in Table 1.

Blood analysisResultReference range

Complete blood countWhite blood cell11.6(4.8–10.9) th/μL
Percent neutrophils76.5(49.0–77.6) %
Percent lymphocytes17.7(11.8–40.8) %
Percent monocytes5(3.70–11.80) %
Percent eosinophils0.2(0–4.8) %
Percent basophils0.3(0–1.3) %
Percent immature granulocytes0.3(0–1) %
Hemoglobin12.6(10.8–14.7) gm/dL
Hematocrit36.8(32.2–42.9) %
Mean corpuscular volume87.4(84–96) fL
Mean corpuscular hemoglobin29.9(28.3–32.3) pg
Mean corpuscular hemoglobin concentration34.2(29.58–33.75) gm/dL
Platelet count212(146–388) th/μL
Red blood cell distribution width CV12(12.20–15.80) %
Red blood cell distribution width SD38.6(38.93–51.44) fL

Complete metabolic panelSodium136(132–143) mmol/L
Potassium3.3(3.5–5.1) mmol/L
Chloride105(98–107) mmol/L
Carbon dioxide23(21–31) mmol/L
Creatinine0.7(0.6–1.2) mg/dL
BUN12(7–25) mg/dL
Calcium8.8(8.6–10.3) mg/dL
Glucose119(70–113) mg/dL
Ammonia30(16–53) umol/L
AST17(13–39) IU/L
ALT15(7–52) IU/L
Alkaline phosphatase73(34–104) IU/L
Albumin4.1(3.7–4.9) gm/dL
Total bilirubin0.3(0.2–1.2) mg/dL

Coagulation studiesPT12.9(10.6–13) second
INR1.11(0.90–1.10) INR
PTT22.8(24–36.7) second

OthersSedimentation rate462–30 mm/hr
C-reactive protein3.3<1 mg/dL
Lactic acid1.2(0.5–1.99) mmol/L
Alcohol serum<10.00<10.00 mg/dL
Alcohol serum calculation<0.01<0.01 gm/dL

SerologyANCA screenNegativeNegative
dsDNA1.5<10 IU/mL
Symphony ANA screen0.1<0.7 ratio
Symphony ANA0.2<0.7 ratio
Complement C3156(87–200) mg/dL
Complement C426(19–52) mg/dL

Infectious studiesHIV antibodiesNonreactiveNonreactive
Aspergillus flavus antibodyNegativeNegative
Aspergillus niger antibodyNegativeNegative
Aspergillus fumigatus antibodyNegativeNegative
Coccidioides antibodyNegativeNegative
Histoplasma antibodyNegativeNegative
Blastomycosis antibodyNegativeNegative
Febrile agglutinin panelNegativeNegative
Respiratory viral panel PCRNegativeNegative

ANCA screen: p-ANCA, c-ANCA, and atypical p-ANCA. Febrile agglutinin panel: P-OX19, POX2, P-OXK, and Brucella. Respiratory viral panel includes adenovirus, coronavirus, influenza A, influenza B, human metapneumovirus, parainfluenza, respiratory syncytial virus, rhinovirus, Enterovirus, Bordetella pertussis, Chlamydophila pneumoniae, and Mycoplasma pneumoniae.

A brain computed tomography (CT) without contrast showed slightly increased low density in the left occipital white matter compared to the right which increased the suspicion of posterior reversible encephalopathy syndrome (PRES), and these images are shown in Figure 1. Herpes simplex virus (HSV) encephalitis and autoimmune epilepsy were also considered in the differential diagnosis. The brain CT with perfusion was negative for stroke. Chest X-ray showed atelectatic changes in the right upper lobe. A CT of the abdomen and pelvis was negative for ovarian teratoma. The patient was started on acyclovir for suspected herpetic encephalitis.

A brain magnetic resonance (MRI) was negative for findings supporting the diagnosis of PRES. The electroencephalogram showed no evidence of seizure activity or epileptiform discharges. Lumbar puncture was performed, and the cerebrospinal fluid (CSF) had a clear appearance. The opening pressure was normal. The CSF glucose was elevated at 91 units. The CSF white blood cell count was 3/μL. Further studies on CSF for ruling out meningitis were done, and they included Cryptococcus neoformans/gattii, Cytomegalovirus, Enterovirus CSF, E. coli K1, Hemophilus influenzae, Human Parechovirus, Listeria monocytogenes, Neisseria meningitidis, Streptococcus agalactiae, Streptococcus pneumoniae, varicella-zoster, and herpes simplex virus 1, 2, and 6, which were negative; details are shown in Table 2.

VariableResultReference range

General analysisCSF appearanceClearClear
CSF WBC30–5/μL
CSF glucose9140–70 mg/dL
CSF total protein2615–45 mg/dL

Infectious studiesCSF Cryptococcus neoformans/gattii antigenNot detectedNot detected
CSF CytomegalovirusNot detectedNot detected
CSF EnterovirusNot detectedNot detected
CSF Escherichia coli K1Not detectedNot detected
CSF Hemophilus influenzaeNot detectedNot detected
CSF herpes simplex virus 1Not detectedNot detected
CSF herpes simplex virus 2Not detectedNot detected
CSF human herpes virus 6Not detectedNot detected
CSF human ParechovirusNot detectedNot detected
CSF Listeria monocytogenesNot detectedNot detected
Neisseria meningitidisNot detectedNot detected
Streptococcus agalactiaeNot detectedNot detected
Streptococcus pneumoniaeNot detectedNot detected
Varicella-zoster virusNot detectedNot detected
CSF West Nile IgM<0.90<0.90
CSF cultureNo growthNo growth

Autoimmune studiesCSF VGKC antibody<20<20 pmol/L
CSF NMDA receptor antibodyNegativeNegative
CSF NMDAR1 antibody, CBANegativeNegative
CSF AMPAR1 antibody, CBANegativeNegative
CSF AMPAR2 antibody, CBANegativeNegative
GABABR antibody, CBANegativeNegative
LGI1 antibody, CBANegativeNegative
CASPR2 antibody, CBANegativeNegative
GAD-65<5<5 IU/mL

VGKC: voltage-gated potassium channel; NMDA: N-methyl-D-aspartate; AMPAR: alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor; GABA: gamma aminobutyric acid B receptor; LGI1: leucine-rich glioma-inactivated 1; CASPR2: contactin-associated protein 2; GAD: glutamic acid decarboxylase.

The infectious disease team was consulted, and doxycycline was added due to the high prevalence of typhus in the area. Febrile agglutinins, West Nile virus, and fungal serologies were also negative (Table 1).

CSF studies for autoimmune epilepsy, including N-methyl-D-aspartate (NMDA) receptor antibodies, glutamic acid decarboxylase (GAD-65) antibodies, and voltage-gated potassium channel (VGKC) antibodies, were negative for autoimmune epilepsy, the more detailed studies in Table 2. Human immunodeficiency virus was negative. Autoimmune panel was negative for antineutrophil cytoplasmic antibodies (ANCAs), antinuclear antibody (ANA), and double stranded DNA (dsDNA) antibodies.

Due to persistent diarrhea during the initial day of admission, a gastrointestinal infectious panel was ordered and was positive for C. jejuni (Table 3).

VariableResultReference range

Gastrointestinal analysisCampylobacterDetectedNot detected
Clostridium difficileNot detectedNot detected
Plesiomonas shigelloidesNot detectedNot detected
SalmonellaNot detectedNot detected
Yersinia enterocoliticaNot detectedNot detected
VibrioNot detectedNot detected
Vibrio choleraeNot detectedNot detected
Enteroaggregative E. coliNot detectedNot detected
Enteropathogenic E. coliNot detectedNot detected
Enterotoxigenic E. coliNot detectedNot detected
Shiga-like toxin-producing E. coliNot detectedNot detected
E. coli O157Not detectedNot detected
Shigella/enteroinvasive E. coliNot detectedNot detected
CryptosporidiumNot detectedNot detected
Cyclospora cayetanensisNot detectedNot detected
Entamoeba histolyticaNot detectedNot detected
Giardia lambliaNot detectedNot detected
AdenovirusNot detectedNot detected
AstrovirusNot detectedNot detected
NorovirusNot detectedNot detected
RotavirusNot detectedNot detected
SapovirusNot detectedNot detected

Based on the clinical scenario of a patient with extraintestinal complications of Campylobacter infection, it was decided to start azithromycin 500 mg per mouth for at least 10 days. The patient showed significant improvement after the first dose and recovered over the next few days prior to discharge.

3. Discussion

We are describing a case of Campylobacter jejuni gastroenteritis associated with acute encephalopathy in an immunocompetent adult. The complex initial presentation with neurological symptoms makes this clinical scenario a diagnostic challenge due to the unfamiliarity of clinicians with this disease.

Campylobacter species belongs to a distinct group of specialized Gram-negative bacteria designated as rRNA superfamily VI [10]. The most important species that can cause human disease are C. jejuni and C. coli [11]. Campylobacters invade the intestinal epithelium using flagella, high molecular weight plasmids, superficial adhesins, and chemotactic factors [12].

Patients infected with C. jejuni gastroenteritis experience acute watery or bloody diarrhea, fever, weight loss, and cramps that last six days on average [11]. Besides the gastrointestinal local infection, Campylobacter species also can cause a range of other clinical manifestations or postinfectious immune disorders [13].

While infection with C. jejuni can occur in patients of all ages, this infection is more prevalent in toddlers and young adults than in other age groups [14]. Despite most of the neurologic complications associated with Campylobacter enteritis have been historically linked to the pediatric population, some of these manifestations have been also described in adults [9].

Our patient had an unusual presentation of C. jejuni gastroenteritis associated with acute encephalopathy. Based on her initial symptoms, she was treated with acyclovir for the suspicion of HSV encephalitis. Moreover, the combination of seizures in association with the abnormalities noted in the mentioned neuroimaging raised the initial suspicion for PRES and autoimmune epilepsy. These diagnoses were ruled out with a brain MRI and a CSF autoimmune panel, respectively [1517].

Other autoimmune systemic diseases including lupus and vasculitis were ruled out with negative ANCA, ANA, and dsDNA. We also considered ADEM following a C. jejuni gastroenteritis in our differential diagnosis. Nonetheless, the MRI did not show increased T2-signal intensity in the white matter which is a characteristic neuroimaging finding in ADEM [4]. Furthermore, patients suffering ADEM only improve with high-dose steroids that our patient never received [4].

Based on Rio Grande Valley demographics with high prevalence of murine typhus in the area, the patient was treated empirically with doxycycline until her agglutinins were negative [18]. In this clinical case, the neurological and gastrointestinal symptoms rapidly resolved once the patient was started on azithromycin for Campylobacter gastroenteritis. Azithromycin is the antibiotic of choice, has good coverage for Campylobacter jejuni, shortens the duration of symptoms, and decreases resistance compared to fluoroquinolones [19, 20].

At this present time, the exact pathophysiology of Campylobacter gastroenteritis associated with encephalopathy is unknown, but it is possible that mechanisms involving antibody cross-reactivity may play a role [9]. For example, it is well known that bidirectional signaling exists between the gastrointestinal tract and the brain in Guillain-Barré syndrome after a C. jejuni infection, where the outer membrane structures of Campylobacter containing sialic acid resemble those seen in the human gangliosides [9].This brings the topic of gut-brain axis, which explains that everything is interconnected: the gut can influence the brain, the brain can influence the gut, and they both can influence and be influenced by the immune system [21].

There are only a few cases of Campylobacter gastroenteritis with encephalopathy in immunocompetent population, and one of them went through a similar analysis process of differential diagnoses, obtained similar workup as in our patient based on the neurological symptoms, age of the patient, immunocompetent status, and severity of symptoms onset, with clinical improvement after starting antibiotics [9].

Due to the low prevalence of Campylobacter-associated encephalopathy in adults, we do not recommend assuming that mental status changes in a patient presenting with Campylobacter gastroenteritis are necessarily associated with the infection. A proper and well-directed workup should be completed to rule out other more frequent and emergent neurological diseases such as bacterial meningitis or vascular disease. We would recommend considering Campylobacter-associated encephalopathy in the differential diagnosis of diarrhea associated with mental status changes.

Conflicts of Interest

The authors declare that they have no conflicts of interest.


  1. B. M. Allos, “Campylobacter jejuni Infections: update on emerging issues and trends,” Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, vol. 32, no. 8, pp. 1201–1206, 2001. View at: Google Scholar
  2. World Health Organization, “Campylobacter World Health Organization newsroom,” 2018, View at: Google Scholar
  3. Centers for Disease Control and Prevention, CDC Yellow Book 2020: Health Information for International Travel, Oxford University Press, New York, NY, USA,  2017.
  4. S. Marziali, E. Picchi, F. Di Giuliano et al., “Acute disseminated encephalomyelitis following Campylobacter jejuni gastroenteritis: case report and review of the literature,” The Neuroradiology Journal, vol. 30, no. 1, pp. 65–70, 2017. View at: Publisher Site | Google Scholar
  5. F. Rocha Cabrero and E. H. Morrison, Miller Fisher Syndrome, StatPearls Publishing, Treasure Island, FL, USA, 2020,
  6. B. M. Allos, “Association between Campylobacter Infection and Guillain-Barré syndrome,” The Journal of Infectious Diseases, vol. 176, no. s2, pp. S125–S128, 1997. View at: Publisher Site | Google Scholar
  7. I. Levy, Y. Weissman, Y. Sivan, J. Ben-Ari, and T. Scheinfeld, “Acute encephalopathy associated with Campylobacter enteritis,” BMJ, vol. 293, no. 6544, p. 424, 1986. View at: Publisher Site | Google Scholar
  8. R. A. Van der Kruijk, M. J. Affourtit, H. P. Endtz, and W. F. M. Arts, “Campylobacter jejuni gastroenteritis and acute encephalopathy,” Journal of Infection, vol. 28, no. 1, pp. 99-100, 1994. View at: Publisher Site | Google Scholar
  9. D. Lepur, V. Peterković, S. B. Kovačević, K. Višković, N. K. Lepur, and M. Kutleša, “Acute encephalopathy associated with Campylobacter jejuni enteritis,” Neurological Sciences, vol. 33, no. 1, pp. 155–158, 2012. View at: Publisher Site | Google Scholar
  10. P. Vandamme, E. Falsen, R. Rossau et al., “Revision of Campylobacter, Helicobacter, and Wolinella taxonomy: emendation of generic descriptions and proposal of Arcobacter gen. nov,” International Journal of Systematic Bacteriology, vol. 41, no. 1, pp. 88–103, 1991. View at: Publisher Site | Google Scholar
  11. S. M. Man, “The clinical importance of emerging Campylobacter species,” Nature Reviews Gastroenterology & Hepatology, vol. 8, no. 12, pp. 669–685, 2011. View at: Publisher Site | Google Scholar
  12. T. M. Wassenaar and M. J. Blaser, “Pathophysiology of Campylobacter jejuni infections of humans,” Microbes and Infection, vol. 1, no. 12, pp. 1023–1033, 1999. View at: Publisher Site | Google Scholar
  13. N. O. Kaakoush, N. Castaño-Rodríguez, H. M. Mitchell, and S. M. Man, “Global epidemiology of Campylobacter infection,” Clinical Microbiology Reviews, vol. 28, no. 3, pp. 687–720, 2015. View at: Publisher Site | Google Scholar
  14. H. L. Nielsen, T. Ejlertsen, J. Engberg, and H. Nielsen, “High incidence of Campylobacter concisus in gastroenteritis in North Jutland, Denmark: a population-based study,” Clinical Microbiology and Infection, vol. 19, no. 5, pp. 445–450, 2013. View at: Publisher Site | Google Scholar
  15. R. Raman, R. Devaramane, G. Mukunda Jagadish, and S. Chowdaiah, “Various imaging manifestations of posterior reversible encephalopathy syndrome (PRES) on magnetic resonance imaging (MRI),” Polish Journal of Radiology, vol. 82, pp. 64–70, 2017. View at: Google Scholar
  16. A. M. L. Quek, J. W. Britton, A. McKeon et al., “Autoimmune epilepsy,” Archives of Neurology, vol. 69, no. 5, pp. 582–593, 2012. View at: Publisher Site | Google Scholar
  17. F. Graus, M. J. Titulaer, R. Balu et al., “A clinical approach to diagnosis of autoimmune encephalitis,” The Lancet Neurology, vol. 15, no. 4, pp. 391–404, 2016. View at: Publisher Site | Google Scholar
  18. Z. Afzal, S. Kallumadanda, F. Wang, V. Hemmige, and D. Musher, “Acute febrile illness and complications due to murine typhus, Texas, USA 1,2,” Emerging Infectious Diseases, vol. 23, no. 8, pp. 1268–1273, 2017. View at: Publisher Site | Google Scholar
  19. A. Ternhag, T. Asikainen, J. Giesecke, and K. Ekdahl, “A meta-analysis on the effects of antibiotic treatment on duration of symptoms caused by infection with Campylobacter species,” Clinical Infectious Diseases, vol. 44, no. 5, pp. 696–700, 2007. View at: Publisher Site | Google Scholar
  20. Y. Yang, K. M. Feye, Z. Shi et al., “A historical review on antibiotic resistance of foodborne Campylobacter,” Frontiers in Microbiology, vol. 10, p. 1509, 2019. View at: Publisher Site | Google Scholar
  21. A. Vojdani and E. Vojdani, “Reaction of antibodies to Campylobacter jejuni and cytolethal distending toxin B with tissues and food antigens,” World Journal of Gastroenterology, vol. 25, no. 9, pp. 1050–1066, 2019. View at: Publisher Site | Google Scholar

Copyright © 2020 Irma Huayanay et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.